" The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates. "
https://www.statnews.com/2019/01/14/shutdown-impact-on-drug-approvals/
Submitted January 14, 2019 at 07:32PM by snailmailz http://bit.ly/2FAupkL
